Shares of Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) saw strong trading volume on Thursday . 1,201,723 shares were traded during mid-day trading, a decline of 24% from the previous session’s volume of 1,586,014 shares.The stock last traded at $8.64 and had previously closed at $8.17.

Several equities research analysts recently weighed in on the stock. Robert W. Baird restated an “outperform” rating and issued a $10.00 price target on shares of Achillion Pharmaceuticals in a research report on Monday, June 6th. Leerink Swann restated a “hold” rating on shares of Achillion Pharmaceuticals in a research report on Sunday, June 12th. Zacks Investment Research upgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 price target on the stock in a research report on Tuesday, April 26th. JMP Securities upgraded shares of Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $13.00 price target on the stock in a research report on Thursday. Finally, Jefferies Group reiterated a “hold” rating on shares of Achillion Pharmaceuticals in a research report on Thursday, May 5th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $10.43.

The company’s market capitalization is $1.25 billion. The stock’s 50 day moving average price is $8.81 and its 200 day moving average price is $8.10.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01. During the same period last year, the company earned ($0.17) earnings per share. On average, equities research analysts predict that Achillion Pharmaceuticals Inc. will post ($0.65) EPS for the current fiscal year.

Several hedge funds recently modified their holdings of the company. Marshall Wace LLP increased its stake in shares of Achillion Pharmaceuticals by 36.8% in the fourth quarter. Marshall Wace LLP now owns 970,862 shares of the biopharmaceutical company’s stock worth $10,476,000 after buying an additional 261,007 shares during the period. Morgan Stanley increased its stake in shares of Achillion Pharmaceuticals by 738.4% in the fourth quarter. Morgan Stanley now owns 233,221 shares of the biopharmaceutical company’s stock worth $2,517,000 after buying an additional 205,405 shares during the period. ProShare Advisors LLC increased its stake in shares of Achillion Pharmaceuticals by 10.1% in the fourth quarter. ProShare Advisors LLC now owns 126,923 shares of the biopharmaceutical company’s stock worth $1,370,000 after buying an additional 11,681 shares during the period. Rhumbline Advisers increased its stake in shares of Achillion Pharmaceuticals by 14.0% in the fourth quarter. Rhumbline Advisers now owns 117,525 shares of the biopharmaceutical company’s stock worth $1,268,000 after buying an additional 14,425 shares during the period. Finally, Swiss National Bank increased its stake in shares of Achillion Pharmaceuticals by 6.8% in the fourth quarter. Swiss National Bank now owns 152,400 shares of the biopharmaceutical company’s stock worth $1,644,000 after buying an additional 9,700 shares during the period.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.